Drug Shortage Report for DURATOCIN

Last updated on 2020-12-16 History
Report ID 129238
Drug Identification Number 02231593
Brand name DURATOCIN
Common or Proper name Carbetocin Injection (ampoules)
Company Name FERRING INC
Market Status CANCELLED POST MARKET
Active Ingredient(s) CARBETOCIN
Strength(s) 100MCG
Dosage form(s) LIQUID SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS
Packaging size 1 mL ampoule - 100 mcg / mL
ATC code H01BB
ATC description POSTERIOR PITUITARY LOBE HORMONES
Reason for shortage Delay in shipping of the drug.
Anticipated start date
Actual start date 2020-10-20
Estimated end date 2020-12-15
Actual end date 2020-12-15
Shortage status Resolved
Updated date 2020-12-16
Company comments Substitute with DURATOCIN 100 mcg room temperature vials. 1 mL vial, 100 mcg / mL; UPC 779170191008; DIN 02496526. Store at: 15°C to 30°C. Available now and in stock; DURATOCIN (carbetocin injection) room temperature vials are indicated for the prevention of postpartum haemorrhage by controlling uterine atony. Duratocin room temperature vials have the same efficacy and safety features as ampoules with expanded indication for vaginal deliveries.
Health Canada comments
Tier 3 Status No
Contact Address 200 YORKLAND BLVD
TORONTO, ONTARIO
CANADA M2J 5C1
Company contact information 1-800-263-4057

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v14 2020-12-16 English Compare
v13 2020-12-15 French Compare
v12 2020-12-15 English Compare
v11 2020-12-09 French Compare
v10 2020-12-09 English Compare
v9 2020-12-01 French Compare
v8 2020-12-01 English Compare
v7 2020-12-01 English Compare
v6 2020-12-01 French Compare
v5 2020-12-01 French Compare
v4 2020-12-01 French Compare
v3 2020-12-01 French Compare
v2 2020-12-01 English Compare
v1 2020-12-01 English Compare

Showing 1 to 14 of 14